# DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease

> **NCT04420598** · PHASE2 · COMPLETED · sponsor: **MedSIR** · enrollment: 41 (actual)

## Conditions studied

- Advanced Breast Cancer
- HER2-positive Breast Cancer
- Brain Metastases
- Leptomeningeal Metastasis

## Interventions

- **DRUG:** Trastuzumab deruxtecan

## Key facts

- **NCT ID:** NCT04420598
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-25
- **Primary completion:** 2021-09-30
- **Final completion:** 2023-04-04
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04420598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04420598, "DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04420598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*